Yahoo Finance Xencor Inc (XNCR) Q1 2024 Earnings: Misses Revenue and Earnings Estimates
Revenue: Reported at $12.8 million for Q1 2024, fell short of the estimated $24.99 million.
Net Loss: Increased to $68.0 million in Q1 2024 from $60.8 million in Q1 2023, fell short of the estimated loss of $42.23 million.
Earnings Per Share (EPS): Recorded at -$1.11, below the estimated -$0.79.
Research and Development Expenses: Decreased to $56.9 million in Q1 2024 from $65.6 million in the previous year.
Cash Position: Ended Q1 2024 with $646.7 million in cash, cash equivalents, and marketable debt securities, down from $697.4 million at the end of 2023.
Financial Guidance: Expects to end 2024 with between $475 million and $525 million in cash, cash equivalents, and marketable debt securities.
On May 9, 2024, Xencor Inc (NASDAQ:XNCR), a clinical-stage biopharmaceutical company, disclosed its financial results for the first quarter ended March 31, 2024, through its 8-K filing. The company, known for developing engineered antibodies for treating cancer and other serious diseases, reported a net loss and a decline in revenue, falling short of analyst expectations.
Financial Performance Overview
Xencor Inc reported a revenue of $12.8 million for Q1 2024, a decrease from $19.0 million in the same period last year, and below the estimated $24.99 million. The company's net loss widened to $68.0 million, or $(1.11) per share, compared to a loss of $60.8 million, or $(1.02) per share in Q1 2023, significantly missing the estimated earnings per share of -$0.79.
Research and development expenses totaled $56.9 million, reflecting a decrease from $65.6 million in Q1 2023, indicating a reduction in spending across multiple clinical-stage programs and wind-down costs on terminated programs. General and administrative expenses remained stable at $13.8 million, aligning closely with the previous year's $14.2 million.
Strategic Developments and Clinical Progress
Dr. Bassil Dahiyat, president and CEO of Xencor, highlighted the advancement of key oncology programs including XmAb819, XmAb808, and XmAb541, all in Phase 1 clinical studies. The company's Xtend antibody half-life extension technology has also seen success, notably with Ultomiris now approved in the U.S. for NMOSD patients, and a promising investigational antibody demonstrating effectiveness in preventing malaria.
The first quarter also saw the appointment of Bart Cornelissen as the new CFO, and the FDA approval of Ultomiris for NMOSD, marking significant milestones for the company.
Financial Position and Outlook
As of March 31, 2024, Xencor's cash, cash equivalents, and marketable debt securities stood at $646.7 million, a decrease from $697.4 million at the end of 2023. The company forecasts ending 2024 with between $475 million and $525 million in these assets, with sufficient cash to fund operations into 2027.
Investor and Analyst Perspectives
Despite the financial shortfall this quarter, Xencor continues to invest in its robust clinical pipeline and technological advancements, which could yield significant long-term benefits. The company's strategic focus on engineered antibodies and proprietary technologies positions it well within the biopharmaceutical sector, despite current financial volatilities.
Xencor Inc plans to participate in upcoming investor conferences, including the RBC Capital Markets Global Healthcare Conference and the BofA Securities Health Care Conference, which may provide further insights into the company's strategies and outlook.
For detailed financial tables and further information on Xencor's Q1 2024 performance, refer to the full earnings report and additional company disclosures.
Explore the complete 8-K earnings release (here) from Xencor Inc for further details.
This article first appeared on GuruFocus.
